News Archive

The data is in, and there is no question that 2013 was the most active year for biotechnology initial public offerings since 2000. During the 12 months ended in December, 38 biotech companies debuted on Wall Street, all but two of which were listed on the Nasdaq exchange, according to FactSet, a Norwalk, Conn.-based provider of financial analytics. The performance of the biotech class of 2013 was rather impressive: As a group, the shares of the newly public companies rose 43% through the end of the year.

When I say in Cambridge, I’m speaking figuratively about Medimmune; Babraham, Melbourn and Granta Park could be described as “Cambridge, but in pretty countryside without the traffic problems”. That aside, the story told at the Cambridge Network meeting today was one of our regions great successes. We were privileged to have an insight provided by Jon Green, VP Business Operations, Medimmune and and Dr Paul Varley, VP Science and Collaborations, Biopharmaceutical Development.

It all started with CAT, Cambridge Antibody Technology, back in the 90s. The company was founded on the development of an antibody technology.

The Centers for Medicare & Medicaid Services has found two leaders from within the agency to spearhead technology and operations in Medicare and Medicaid, naming David Nelson CIO and Tim Love COO.

The two long-time CMS staffers, both former members of the military, replace two other long-time agency leaders and are overseeing the most significant health coverage and regulatory expansions in the agency’s history.

The race for the $1,000 genome has been won.

Biotech firm Illumina sent shockwaves through the biotech industry this week by unveiling a new machine that can sequence a full human genome for $1,000. Until Illumina came along, genome sequencing cost approximately $5,000, which is out of range for many patients.

In 2011, the executives of Savi Technology faced a classic business problem. To cut costs, they needed to close one of their three offices and consolidate their workers in another. Their choices were Mountain View, Calif., home to their hardware engineers; Lexington, Ky., where officials were dangling a wide array of tax breaks if Savi expanded there; and Alexandria, in an office park a stone’s throw from the Capital Beltway.

The company’s engineers warned executives that they would have trouble finding enough similarly skilled employees outside Silicon Valley, especially in the Washington area. The executives decided to ditch California anyway and move their headquarters to Virginia.

A new MRSA test that helps you detect recently emerged strains has earned the Food and Drug Administration’s market approval, says manufacturer BD Diagnostics.

The BD MAX MRSA XT Assay is the company’s second test that can detect MRSA strains with the mecC gene, but the first that can do so via a nasal swab. The earlier version, released in 2013, could be used only on patients about to undergo surgery.

Researchers and physicians at The Johns Hopkins University will collaborate with Belgian nanoelectronics research center imec to advance silicon applications in health care, beginning with development of a point-of-care device to enable a broad range of clinical tests to be performed outside the laboratory. The collaboration, announced today, will combine the Johns Hopkins clinical and research expertise with imec’s technical capabilities. The two organizations plan to forge strategic ties with additional collaborators across the value chain in the health care and technology sectors.

“Johns Hopkins has always prioritized innovative and transformative research opportunities,” said Landon King, M.D., the David Marine Professor of Medicine and executive vice dean of the school of medicine. “Our new collaboration with imec is such an opportunity, and we very much look forward to leveraging our respective strengths across the university in biomedical and nanotechnology research to improve patient diagnosis and care throughout the world.”

The 8th Annual Postdoc Conference and Career Fair is April 24, 2013 at the Bethesda North Marriott Conference Center. The event draws and average of 500 postdoctoral fellows from federal and university laboratories who are finishing their fellowships in the STEM fields and are seeking professional employment. The conference portion of the event runs concurrently with the career fair, and focuses on such topics as preparing for an interview and exploring non-traditional careers. The conference is organized by a symposium of government, private, educational and economic development organizations. Company registration for the career fair portion is now open and starts at $500.

Thinking about Big Pharma’s relationship with the biotech industry last week at the JP Morgan Healthcare Conference in San Francisco reminded me of an old physical education teacher I had in 7th grade.

This guy was feared for his patented “pinch.” He would grab misbehaving teenage boys by the clavicle, and squeeze so hard that his thumb and index finger almost completely wrapped around the bone. He would then drag the pimply, 100-pound punk to his office for a scolding.

New data show that local venture-capital deals have come roaring back after the economic downturn.

Investors pumped $1.54 billion into Washington area companies last year, the largest sum in more than a decade. The figures suggest that venture capitalists may be more bullish on the state of the economy and are loosening their purse strings as a result.